Dynavax Technologies Corp
Suletud
SektorTervishoid
15.49
Ülevaade
Aktsiahinna muutus
24h
Min
15.49
Max
15.49
Sissetulek | 8.2M 27M |
|---|---|
Müük | -566K 95M |
Kasumimarginaal | 28.381 |
Töötajad | 405 |
EBITDA | 7M 32M |
Järgmine tulemuste avaldamine | 19. veebr 2026 |
|---|
Turukapital | 625M 1.8B |
|---|---|
Eelmine avamishind | 15.49 |
Eelmine sulgemishind | 15.49 |
Uudiste sentiment
By Acuity
18%
82%
26 / 352 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Very Strong Bearish Evidence
Dynavax Technologies Corp Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Dynavax Technologies Corp Prognoos
Sentiment
By Acuity
26 / 352 Pingereas Tervishoid
Uudiste sentiment
Väga tugevad tõusu märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Dynavax Technologies Corp
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
